Study wrapper · #1107
Resolution of anhedonia-like symptoms in patients treated for obesity with tirzepatide: A three-case series.
Nadolsky S, Kessel S, Krumm ZA, et al. Obesity pillars. 2026.
DOI: 10.1016/j.obpill.2026.100302PubMed: 42518361
Editor's note
A three-case series flagging a possible neurobehavioral effect of high-dose tirzepatide, with symptom improvement reported after dose reduction. As an uncontrolled case series it raises a monitoring consideration rather than establishing incidence or causation.
Plain-language abstract
This three-patient case series describes anhedonia-like symptoms, such as reduced motivation and emotional flatness, in women on high-dose tirzepatide, with improvement after dose reduction. The small, uncontrolled design means the link remains tentative.
Related coverage
Weak / none
Cost-effectiveness of tirzepatide versus semaglutide for patients with obesity or overweight in the US: evidence from the SURMOUNT-5 head-to-head phase-3 trial.
Journal of medical economicsn=——2026
Weak / none
Tirzepatide attenuates lipopolysaccharide-induced acute lung injury via AMPK/NF-κB signaling pathway.
Tissue & celln=——2026
Supported
Tirzepatide and SGLT2 Inhibitors for Heart Failure With Preserved Ejection Fraction and Obesity: Entering a New Cardiometabolic Therapeutic Era.
Endocrinology, diabetes & metabolismn=——2026